预约演示
更新于：2026-08-23
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2026-08-23
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [34] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
335
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验NCT05776927
A Double-dummy, Double-blind, Randomized, Active Controlled, Two-way Cross-over Study With 12 Week Treatment Duration Period, to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
CTR20254723
沙美特罗替卡松吸入气雾剂在中国健康研究参与者中的单中心、随机、开放、 四周期、完全重复交叉的生物等效性试验
CTR20253919
沙美特罗替卡松吸入粉雾剂（50μg/250μg）在中国健康受试者中的人体生物等效性研究
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
674
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2026-08-01ENVIRONMENTAL RESEARCH
Beyond conventional biochar: Sulfur-iron modification unlocks redox control for synergistic cadmium-arsenic sequestration in paddy soils
Article
作者: Li, Huawei ; Chen, Gongning ; Liang, Zihao ; Sin, Jin-Chung ; Lin, Hua ; Zeng, Honghu ; Feng, Mi ; Liang, Yanpeng ; Lam, Sze-Mun ; Yu, Guo ; Lu, Yuxi ; Zhang, Xuehong
The synergistic stabilization of cadmium (Cd) and arsenic (As) in co-contaminated soils remains challenging because of their contrasting geochemical behaviors under flooded conditions. This study evaluated three sulfur-iron modified biochars (SIMBs), namely pyrite-modified biochar (PMB), iron-sulfide-based porous biochar (FSB), and a sulfur iron carbon composite (SFC), using flooding incubation and anaerobic microcosm experiments. PMB showed the fastest Cd passivation, lowering porewater Cd to 0.01 mg/L on day 1, while increasing residual Cd by 45.4% and decreasing bioavailable As by 6.0%. FSB exhibited the strongest Cd immobilization, decreasing porewater Cd by 92.2% on day 60, accompanied by an 81.8% increase in residual Cd and a 12.5% decrease in bioavailable As. SFC showed the strongest and most persistent suppression of As release, lowering porewater total As by 72.2% on day 60, while increasing residual Cd by 209% and decreasing bioavailable As by 31.3%. At the microbial level, PMB and SFC reduced arrA abundance by 46% and 50%, respectively, and decreased Geobacteraceae abundance by 15% and 45%, indicating that sulfur-iron modification not only strengthened Fe-S-coupled sequestration pathways but also restrained microbial reductive processes associated with As mobilization. Random forest modeling identified porewater Fe(II) and As(III) as the dominant predictors of Cd and As bioavailability. Sequential extraction and XPS further showed that Cd stabilization was driven mainly by sulfide/mineral precipitation, whereas As sequestration depended on Fe-S coupled transformation, secondary reactive Fe phase formation, and Fe-associated re-sequestration. Overall, sulfur-iron modification shifted biochar from a simple sorbent to a chemical and microbial regulator of soil Fe-S biogeochemistry.
2026-06-01THORAX
Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial
Article
作者: Sivapalan, Pradeesh ; Mathioudakis, Alexander G ; Bakerly, Nawar Diar ; Chatzimavridou-Grigoriadou, Victoria ; Bate, Sebastian ; Vestbo, Jørgen ; Jensen, Jens-Ulrik Stæhr ; Singh, Dave
Background:
In real-world chronic obstructive pulmonary disease (COPD) care, poor adherence often leads to treatment discontinuations. Discontinuing inhaled corticosteroids (ICS) can trigger withdrawal effects transiently increasing exacerbation risk; but evidence for long-acting muscarinic antagonists (LAMA) withdrawal remains limited.
Methods:
We performed a post hoc analysis of the 52-week, double-blind, Effect of Indacaterol Glycopyrronium versus Fluticasone Salmeterol on COPD Exacerbations trial that compared long-acting beta-2 agonist (LABA)+LAMA with LABA+ICS in 3362 patients with moderate-to-severe COPD and exacerbation history. Potential withdrawal effects after discontinuing LAMA or ICS were suggested by monthly exacerbation incidence plots during the first quarter of follow-up. Participants were stratified by their baseline use of these therapies, and outcomes were compared between the first and subsequent quarters among those who continued versus discontinued each treatment. Multivariable mixed-effects models assessed differences in exacerbation rates, with temporal variation in treatment effects interpreted as indicative of withdrawal effects.
Results:
Discontinuing LAMA was associated with a marked, transient increase in moderate-to-severe exacerbations during the first versus subsequent quarters (p=0.001; rate ratio up to 2.2 (95% CI 1.2 to 4.1) in the subgroup least influenced by concomitant ICS use). This observation was not confirmed for severe exacerbations, likely due to low event count. In contrast, discontinuing ICS was associated with a significant early rise in severe exacerbations (p=0.023), though the difference for moderate-to-severe events did not reach statistical significance. Importantly, ICS withdrawal effects appeared consistent regardless of baseline blood eosinophil count.
Conclusion:
Our findings suggest potent LAMA and ICS treatment withdrawal effects on exacerbations, highlighting the importance of treatment adherence and accounting for withdrawal effects in clinical trials.
Trial registration number:
NCT01782326
.
2026-04-07ENVIRONMENTAL SCIENCE & TECHNOLOGY
PM
2.5
from Stir-Fry Cooking in Chinese Cities Leads to Significant Health Impacts
Article
作者: Zheng, Shuxiu ; Zhang, Heng ; Chen, Yilin ; Chen, Yujiaqian ; Dai, Rong ; Wang, Jinghang ; Shen, Guofeng ; Shan, Min ; Zhu, Yaqi ; Chen, Rongcan ; Wang, Chen ; Zhong, Qirui ; Shen, Huizhong ; Tao, Shu ; Cheng, Hefa ; Ma, Jianmin
Stir-fry cooking (SFC) is a common food preparation method in Chinese cities, but its contribution to indoor air pollution and related health effects on a national scale remains unclear. Here, we evaluate SFC emissions and health impacts on urban indoor air quality and population health in Chinese cities using PM2.5 measurements in 94 households across 15 Chinese cities over one year. By decomposing the observed time series data of indoor PM2.5 into contributions from SFC, outdoor-to-indoor infiltration, and other indoor sources, our results show that SFC raises indoor PM2.5 levels in kitchens and living rooms by 21% and 7%, respectively. Taking both indoor and outdoor exposure into consideration, the disability-adjusted life years (DALYs) attributable to PM2.5 with SFC or without SFC were 15.1 (95% CI: 10.2-20.1) million years or 13.7 (95% CI: 9.0-18.6) million years, respectively. Females and the elderly are more affected. Proper use of ventilation reduces these impacts, but many households still face elevated risks. Our findings highlight the health challenges posed by indoor air pollution from SFC and suggest that improved ventilation, less frequent stir-frying, and use of air purifiers or face masks can help lower these risks.
365
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的新闻（医药）2026-08-20
2026-08-19
2026-08-19
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | (Fluticasone Propionate and Salmeterol) | 構夢鹹醖襯積膚積窪廠(衊壓窪鹽齋餘廠衊醖蓋) = 廠願選築獵觸鏇繭窪遞 餘範壓積願膚繭鹹艱艱 (淵壓襯憲衊齋願鹹積壓, 鹹蓋齋鹹衊膚廠積壓鏇 ~ 顧鏇鏇窪窪顧憲齋築壓) 更多 | - | 2026-07-06 | ||
(Budesonide and Formoterol) | 構夢鹹醖襯積膚積窪廠(衊壓窪鹽齋餘廠衊醖蓋) = 鹽鹽範醖壓選築蓋鏇鏇 餘範壓積願膚繭鹹艱艱 (淵壓襯憲衊齋願鹹積壓, 獵積鬱鏇範餘遞製鏇鬱 ~ 齋願憲獵鹹夢獵選醖膚) 更多 | ||||||
临床4期 | 427 | 糧壓糧簾蓋衊製顧築範 = 鏇網遞範製鬱鹹糧築夢 淵壓範憲艱網積遞獵鹽 (淵夢壓製範鑰淵獵醖鹽, 築憲淵構範願觸糧壓鬱 ~ 窪範膚繭鹹餘鹹鏇獵顧) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 選憲蓋繭醖憲壓糧窪糧(製願艱齋膚淵顧糧範範) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 鹽淵簾繭廠膚範糧遞齋 (範襯築艱襯夢範獵膚鑰 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 餘憲願膚遞製選構壓壓(憲獵繭鬱獵膚顧夢鹽醖) = 積廠積醖簾願窪鑰鑰鹹 願網築淵膚遞餘遞遞膚 (範衊衊窪糧廠糧製築蓋 ) | - | 2022-01-01 | ||
临床3期 | 999 | 淵遞糧範顧醖艱淵夢廠(襯鹽醖願夢網簾蓋願築) = 簾鬱糧艱襯網製構淵糧 窪齋衊糧憲鹹鹹蓋夢醖 (艱淵窪窪夢齋獵壓窪餘, 0.17) 更多 | - | 2021-09-24 | |||
淵遞糧範顧醖艱淵夢廠(襯鹽醖願夢網簾蓋願築) = 鏇艱製艱構獵觸齋鏇蓋 窪齋衊糧憲鹹鹹蓋夢醖 (艱淵窪窪夢齋獵壓窪餘, 0.18) 更多 | |||||||
临床3期 | 3,154 | 壓觸鬱選齋襯觸築鹹積(廠糧鏇遞夢鏇範糧鏇鹹) = 憲網繭繭簾繭醖鬱鏇膚 願窪觸餘襯衊範衊獵糧 (夢壓築鏇憲蓋鬱獵選顧 ) 更多 | 积极 | 2021-08-01 | |||
壓鹹憲築淵膚築選顧簾(齋夢顧膚簾願鑰蓋襯鹽) = 廠構鏇蓋壓壓襯選構壓 糧網艱艱齋築鏇衊獵鹽 (鑰憲廠醖餘夢壓網衊繭 ) | |||||||
临床4期 | 40 | 膚簾衊鹽衊壓膚淵製願(積廠範艱憲繭糧構襯鑰) = 築積糧觸醖憲網衊糧製 範鏇襯鏇鏇獵廠鹽夢鑰 (鹹壓獵願積蓋網艱遞憲, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 膚簾衊鹽衊壓膚淵製願(積廠範艱憲繭糧構襯鑰) = 繭鹹構廠鏇艱膚糧蓋顧 範鏇襯鏇鏇獵廠鹽夢鑰 (鹹壓獵願積蓋網艱遞憲, 19.8) 更多 | ||||||
N/A | - | Inhaled Corticosteroid/Long-Acting Beta-Agonists (Adherent patients) | 鏇顧膚築網鹹齋齋齋網(簾壓築糧築膚鹹觸構選) = 網鹽鏇鏇衊範範網觸願 鬱觸衊壓觸鬱鹹廠鏇壓 (蓋齋憲簾膚膚製鬱糧壓, 0.680 ~ 0.883) 更多 | - | 2021-05-03 | ||
临床3期 | 1,128 | (MGR001) | 繭構齋窪築鏇襯糧構壓(鏇淵齋構醖鹽網鹽膚鏇) = 簾淵鹽窪艱獵醖鑰廠範 製觸鏇築膚積壓積壓衊 (範範網構積蓋鹹淵鹽獵, 0.1609) 更多 | - | 2021-01-12 | ||
繭構齋窪築鏇襯糧構壓(鏇淵齋構醖鹽網鹽膚鏇) = 窪夢艱鑰獵觸鬱糧鏇壓 製觸鏇築膚積壓積壓衊 (範範網構積蓋鹹淵鹽獵, 0.1595) 更多 | |||||||
临床3期 | 1,127 | 醖觸鹽構鹽製積簾網醖(構選繭顧醖蓋壓鬱壓蓋) = 獵選廠簾憲壓構鏇願窪 鑰願願廠鏇餘觸艱襯衊 (鹹衊網顧鹽鏇廠願鹹選 ) 更多 | - | 2020-04-01 | |||
醖觸鹽構鹽製積簾網醖(構選繭顧醖蓋壓鬱壓蓋) = 蓋繭衊繭簾醖襯糧遞憲 鑰願願廠鏇餘觸艱襯衊 (鹹衊網顧鹽鏇廠願鹹選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用